Edition:
United Kingdom

Mersana Therapeutics Inc (MRSN.OQ)

MRSN.OQ on NASDAQ Stock Exchange Global Select Market

16.03USD
7:28pm GMT
Change (% chg)

$-1.45 (-8.30%)
Prev Close
$17.48
Open
$17.62
Day's High
$17.88
Day's Low
$15.79
Volume
36,709
Avg. Vol
22,828
52-wk High
$21.01
52-wk Low
$12.75

Chart for

About

Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design... (more)

Overall

Beta: --
Market Cap(Mil.): $429.84
Shares Outstanding(Mil.): 22.71
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Mersana Announces First Patient Dosed With XMT-1536 In Phase 1 Study In Patients With NaPi2b-Expressing Tumors

* MERSANA ANNOUNCES FIRST PATIENT DOSED WITH XMT-1536 IN PHASE 1 STUDY IN PATIENTS WITH NAPI2B-EXPRESSING TUMORS Source text for Eikon: Further company coverage:

12 Dec 2017

BRIEF-Mersana announces third quarter loss of $0.35 per share

* Mersana announces third quarter 2017 financial results and provides business updates

09 Nov 2017

BRIEF-Mersana announces FDA clearance of IND application for XMT-1536

* Mersana announces FDA clearance of IND application for XMT-1536, a first-in-class antibody drug conjugate targeting NaPi2b

30 Oct 2017

BRIEF-Mersana Therapeutics increases size of board and appoints Lawrence Alleva as class III director‍​

* Mersana Therapeutics Inc - Increased size of the board from six to seven directors and appointed Lawrence M. Alleva to serve as a class III director‍​ Source text: (http://bit.ly/2j4r2t3) Further company coverage:

06 Sep 2017

BRIEF-Mersana Q2 loss per share $6.33

* Mersana announces second quarter 2017 financial results and provides business updates

11 Aug 2017

BRIEF-Mersana Therapeutics says Pfizer reports 9.8 percent passive stake in Mersana as of July 3 - SEC Filing

* Pfizer Inc. reports 9.8 percent passive stake in Mersana Therapeutics Inc as of July 3 - sec filing Source text for Eikon: Further company coverage:

13 Jul 2017

BRIEF-Rock Springs Capital Management reports 6.8 pct passive stake in Mersana Therapeutics as of June 28, 2017

* Rock Springs Capital Management LP reports a 6.8 percent passive stake in Mersana Therapeutics Inc as of June 28, 2017 - sec filing Source text (http://bit.ly/2uTwTCc) Further company coverage:

07 Jul 2017

BRIEF-Mersana Therapeutics announces pricing of initial public offering

* Mersana Therapeutics announces pricing of initial public offering

28 Jun 2017

Earnings vs. Estimates